Matthew E. Korenberg

October 13, 2026

Palvella Therapeutics Shares New Data at Dermatology Conference. Palvella Therapeutics presented three posters at the Fall Clinical Dermatology 2026 conference, sharing new data on microcystic lymphatic malformations and DSAP. This update highlights ongoing research in the company's key therapeutic areas. Meanwhile, HC Wainwright lowered its price target to $246 while maintaining its stance on the stock.

September 28, 2026

Lifecore Biomedical to be acquired by Webster Equity Partners. Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.

October 8, 2026

Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript. Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.